FREE SHIPPING ON ORDERS OVER $200
Laboratory research vial labeled TB-500.

TB-500 Peptide Research: Thymosin Beta-4 Fragment, Actin and Wound-Model Findings

TB-500 peptide research is often discussed together with thymosin beta-4, actin signaling, cell migration, and wound-model research. This report separates findings on the short TB-500 fragment from studies of the full-length thymosin beta-4 molecule. For context, see the BPC-157 and TB-500 comparison, how to read model-specific results, and peptide identity and analytical methods.

In analytical papers, TB-500 has been identified as an N-terminally acetylated thymosin beta-4 fragment, Ac-LKKTETQ, corresponding to residues 17–23. A common name alone does not establish the composition of a sample; the sequence and analytical characterization matter. HealthLab lists a TB-500 5 mg research material in its catalog for research use only.

What the mouse wound-model study reported

Philp and colleagues (2003) compared full-length thymosin beta-4 and a synthetic seven-amino-acid peptide, LKKTETQ, in dermal-wound models involving diabetic db/db mice and aged mice. In the diabetic-mouse groups, the paper reported greater wound contraction and collagen deposition with full-length thymosin beta-4; it reported no difference in keratinocyte migration, and the wounds in all diabetic animals were almost completely covered by day 8. In 26-month-old mice, the authors reported delayed wound measurements in controls and increases in keratinocyte migration, wound contraction, and collagen deposition in thymosin beta-4-treated animals. The LKKTETQ fragment produced a result comparable to the parent molecule in the aged animals in that experiment. (Philp et al., 2003; PMID 12581423.)

These are findings from defined mouse models. The paper tested LKKTETQ and full-length thymosin beta-4, not every material labeled TB-500 and not the HealthLab catalog material. The unchanged keratinocyte-migration measure in the diabetic-mouse groups is part of the reported result and should not be left out when summarizing the study.

TB-500 and metabolite research produced a mixed result

A 2024 analytical and cell-based study tracked TB-500 and metabolites in human-serum and enzyme systems and in rat samples. In its fibroblast experiments, the authors reported no cytotoxicity for the parent material or its tested metabolites under the study conditions. Of the compounds tested in the wound-related cell assay, Ac-LKKTE—not the parent TB-500—showed a statistically significant activity compared with the control. The authors proposed that an earlier reported activity might involve a metabolite rather than the parent form. This is a specific in-vitro result, not a general conclusion about all TB-500 samples or outcomes. (Rahaman et al., 2024; PMID 38382158.)

This study is important because its positive and negative results point in different directions: the tested parent TB-500 was not cytotoxic in the assay, but the statistically significant wound-related cell result was reported for a metabolite. It therefore does not support treating TB-500 and its breakdown products as interchangeable.

What the analytical studies established

Esposito and colleagues (2012) used high-performance liquid chromatography and mass spectrometry to identify Ac-LKKTETQ in a product called TB-500 and described analytical detection methods. Ho and colleagues (2012) developed an LC-MS method for TB-500 and metabolites in equine urine and plasma, including samples from horses administered the material. These papers addressed chemical identification and detection; they were not human efficacy trials. (PMIDs 22962027 and 23084823.)

Full-length thymosin beta-4 is not the same as TB-500

Much of the thymosin beta-4 literature investigates the 43-amino-acid parent peptide. TB-500 is commonly used for the shorter Ac-LKKTETQ fragment. A result from a thymosin beta-4 study cannot automatically be attributed to TB-500, and a study of the unacetylated LKKTETQ sequence does not automatically characterize an acetylated TB-500 sample. Researchers should check the exact material described in each paper before comparing findings.

The phrase “TB-500 wound-healing research” is used here as a searchable description of the experimental literature, not as a statement that a HealthLab product heals wounds, repairs tendons, changes inflammation, or produces any other effect in people or animals.

Regulatory and safety record: scope matters

In its July 2026 review of TB-500-related bulk substances nominated for possible use in compounding, FDA stated that it had not identified clinical studies or human exposure data for TB-500 via any route in the nomination materials it reviewed and described potential human safety as unknown. FDA’s separate compounding-risk information flags potential immunogenicity concerns for certain routes, including possible aggregation and peptide-related impurities. Those statements concern evaluation of compounded drug substances; they are not test results for the HealthLab research material. (FDA Pharmacy Compounding Advisory Committee materials, July 2026; FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.”)

For laboratory interpretation, keep the distinctions visible: full-length thymosin beta-4 versus TB-500 fragment; acetylated parent versus metabolites; mouse or cell model versus human evidence; and analytical identification versus a biological-outcome experiment. Related articles include BPC-157 and TB-500 research distinctions and peptide identity and stability methods.

Research references

  • Philp D et al. “Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.” 2003. PMID 12581423.
  • Esposito S et al. “Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500.” 2012. PMID 22962027.
  • Ho EN et al. “Doping control analysis of TB-500 … in equine urine and plasma by liquid chromatography-mass spectrometry.” 2012. PMID 23084823.
  • Rahaman KA et al. “Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats … and their screening by wound healing activities in-vitro.” 2024. PMID 38382158.
  • FDA Pharmacy Compounding Advisory Committee meeting materials, July 23–24, 2026; FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.”

For Research Use Only. Not for human or veterinary use, consumption, or injection. No dosing, administration, reconstitution, or treatment instructions are provided. The findings summarized here are reports of specific studies and are not claims about HealthLab products.

Leave a Reply

Shopping cart

1

Subtotal: $69.50

View cartCheckout